文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

双靶向HER3-EGFR抗体MEHD7945A联合电离辐射在宫颈癌细胞中增强抗肿瘤疗效

Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-01-17

该研究评估EGFR与HER3共表达作为局部晚期宫颈癌预后生物标志物的价值,并在EGFR/HER3阳性宫颈癌细胞系及A431异种移植瘤中检验双抗体MEHD7945A联合电离辐射的疗效。结果显示FIGO IVB期肿瘤共表达EGFR和HER3者中位总生存期较短,联合治疗可增强放疗反应并增加DNA损伤与免疫原性细胞死亡。

要点

  • FIGO IVB期宫颈癌中EGFR/HER3共表达者中位总生存期14.6个月,非共表达者23.1个月。
  • MEHD7945A联合电离辐射在A431异种移植瘤中显著抑制肿瘤生长并增加cleaved caspase-3表达。
  • 联合治疗在A431和CaSki细胞中增加DNA损伤与细胞死亡,并抑制MAPK和AKT通路。

核心结论

  • 双靶向EGFR和HER3的特异性抗体MEHD7945A可增强电离辐射疗效,EGFR和HER3共表达可能具有预后价值,但需更大样本验证。

研究设计与样本

  • 研究对72例局部晚期宫颈癌活检组织行EGFR和HER3免疫组化检测,并在2株EGFR/HER3阳性宫颈癌细胞系(A431和CaSki)及A431细胞异种移植瘤中评估MEHD7945A联合电离辐射的抗肿瘤效应及机制。

主要发现

  • 22例FIGO IVB期宫颈癌活检中仅7例共表达EGFR和HER3;共表达者中位总生存期14.6个月,非共表达者23.1个月。
  • 在A431异种移植瘤中,MEHD7945A显著增强电离辐射反应,表现为肿瘤生长减少和cleaved caspase-3表达增加。
  • 在A431和CaSki细胞中,联合治疗增加DNA损伤和细胞死亡(特别是免疫原性细胞死亡),并通过抑制MAPK和AKT通路降低细胞存活。
  • 电离辐射、MEHD7945A和顺铂三联组合观察到相加效应。

临床怎么用

  • EGFR和HER3共表达检测可能有助于识别局部晚期宫颈癌预后较差的患者,双抗体MEHD7945A联合放疗及顺铂的策略值得进一步临床转化研究。

局限性

  • 研究仅为初步结果,EGFR和HER3共表达的预后价值需在更大样本中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The outcome of locally advanced cervical cancer (LACC) is dismal. Biomarkers are needed to individualize treatments and to improve patient outcomes. Here, we investigated whether coexpression of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) could be an outcome prognostic biomarker, and whether targeting both EGFR and HER3 with a dual antibody (MEHD7945A) enhanced ionizing radiation (IR) efficacy. METHODS AND MATERIALS: Expression of EGFR and HER3 was evaluated by immunohistochemistry in cancer biopsies (n = 72 patients with LACC). The antitumor effects of the MEHD7945A and IR combotherapy were assessed in 2 EGFR- and HER3-positive cervical cancer cell lines (A431 and CaSki) and in A431 cell xenografts. The mechanisms involved in tumor cell radiosensitization were also studied. The interaction of MEHD7945A, IR, and cisplatin was evaluated using dose-response matrix data. RESULTS: EGFR and HER3 were coexpressed in only in 7 of the 22 biopsies of FIGO IVB cervix cancer. The median overall survival was 14.6 months and 23.1 months in patients with FIGO IVB tumors that coexpressed or did not coexpress EGFR and HER3, respectively. In mice xenografted with A431 (squamous cell carcinoma) cells, MEHD7945A significantly increased IR response by reducing tumor growth and increasing cleaved caspase-3 expression. In A431 and CaSki cells, the combotherapy increased DNA damage and cell death, particularly immunogenic cell death, and decreased survival by inhibiting the MAPK and AKT pathways. An additive effect was observed when IR, MEHD7945A, and cisplatin were combined. CONCLUSIONS: Targeting EGFR and HER3 with a specific dual antibody enhanced IR efficacy. These preliminary results and the prognostic value of EGFR and HER3 coexpression should be confirmed in a larger sample.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bourillon L, Demontoy S, Lenglet A, et al. Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells. Int J Radiat Oncol Biol Phys. 2020. PMID: 31959545. doi:10.1016/j.ijrobp.2019.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。